XORTX Therapeutics Inc. is a late-stage clinical pharmaceutical company focused on developing therapies for gout and progressive kidney disease. While it has a solid current ratio of 1.62, indicating good liquidity, its negative ROE and ROA suggest ongoing financial struggles. The low market cap of $888.38K raises concerns about investor confidence and potential growth. Overall, the company shows promise in its niche but faces significant challenges in profitability and market perception.
Loading financial metrics...
Company has $1.2M in cash but burned $738K last quarter. At this burn rate, only 1.6 quarters of runway remain without additional financing.
Company posted a loss of $-1.9M over the last year, representing Infinity% of revenue.
Operating cash flow has been negative for 3 consecutive quarters, burning $3.0M over the last year.
Fortress balance sheet: cash covers total debt 20×, providing significant financial flexibility.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Biotechnology companies of a similar size
Based on 2025-Q3 (September 30, 2025)